Literature DB >> 35442937

In Reply: Permanent Cerebrospinal Fluid Diversion in Adults With Posterior Fossa Tumors: Incidence and Predictors.

Hassan Saad1, David Bray, Ali Alawieh, Kimberly Hoang.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35442937      PMCID： PMC9514758          DOI： 10.1227/neu.0000000000001992

Source DB:  PubMed          Journal:  Neurosurgery        ISSN： 0148-396X            Impact factor:   5.315


× No keyword cloud information.
  5 in total

1.  Letter: Permanent Cerebrospinal Fluid Diversion in Adults With Posterior Fossa Tumors: Incidence and Predictors.

Authors:  Anis Choucha; Nathan Beucler; Henry Dufour
Journal:  Neurosurgery       Date:  2022-04-08       Impact factor: 4.654

2.  Childhood hydrocephalus secondary to posterior fossa tumor is both an intra- and extraaxial process.

Authors:  Grant A Bateman; Mark Fiorentino
Journal:  J Neurosurg Pediatr       Date:  2016-04-01       Impact factor: 2.375

3.  Endoscopic Third Ventriculostomy before Posterior Fossa Tumor Surgery in Adult Patients.

Authors:  Sascha Marx; Ahmed El Damaty; Jotham Manwaring; Ehab El Refaee; Steffen Fleck; Michael Fritsch; Michael R Gaab; H W S Schroeder; Jörg Baldauf
Journal:  J Neurol Surg A Cent Eur Neurosurg       Date:  2017-12-14       Impact factor: 1.268

4.  Permanent Cerebrospinal Fluid Diversion in Adults With Posterior Fossa Tumors: Incidence and Predictors.

Authors:  Hassan Saad; David P Bray; J Tanner McMahon; Brandon D Philbrick; Reem A Dawoud; J Miller Douglas; Segun Adeagbo; Steven K Yarmoska; Matthew Agam; Jocelyn Chow; Gustavo Pradilla; Jeffrey J Olson; Ali Alawieh; Kimberly Hoang
Journal:  Neurosurgery       Date:  2021-11-18       Impact factor: 5.315

5.  Endoscopic third ventriculostomy before surgery of third ventricle and posterior fossa tumours decreases the risk of secondary hydrocephalus and early postoperative complications.

Authors:  Pawel Tabakow; Artur Weiser; Malgorzata Burzynska; Przemyslaw Blauciak
Journal:  Neurosurg Rev       Date:  2021-07-22       Impact factor: 2.800
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.